The goal of this observational study is to learn if the novel biomarker Heat shock protein 47 (HSP47) can be used as a prognostic marker for vascular disease in people with acute venous thromboembolism (VTE), myocardial infarction (AMI) or ischaemic stroke compared to healthy volunteers. The main questions it aims to answer are: 1. Are platelet levels of HSP47 higher in patients with acute VTE, AMI or stroke, compared to healthy volunteers. 2. Does platelet levels of HSP47 remain elevated in patients with acute thrombotic events compared to healthy volunteers at 3 and 12-months of follow-up. 3. Are platelet levels of HSP47 postively associated with platelet function and negatively associated with fibrinolytic capacity in patients with an acute thrombotic event. Participants with VTE, AMI or stroke will be giving a blood sample at diagnosis and again after 3 and 12 months of follow-up. Healthy volunteers will be giving a blood sample once.
Study Type
OBSERVATIONAL
Enrollment
340
Aarhus University Hospital
Aarhus, Central Region, Denmark
RECRUITINGDeutsches Herzzentrum de Charité
Berlin, State of Berlin, Germany
RECRUITINGPlatelet levels of heat shock protein 47 (HSP47) in patients with thrombosis compared to healthy controls
The level of HSP47 on platelets will be measured in a bloodsample. It will be measured using proteomics and flow cytometry.
Time frame: From enrollment to end of follow-up at 12 months after enrollment. At 3 time points.
Changes in platelet levels of HSP47 over time in patients with thrombosis
The level of HSP47 on platelets will be measured in a bloodsample. It will be measured using proteomics and flow cytometry.
Time frame: From enrollment to 12 months of follow-up. Measured at 3 time points.
Platelet levels of HSP47 in association to platelet function
The level of HSP47 on platelets will be measured in a bloodsample. It will be measured using proteomics and flow cytometry. Platelet function will be assessed by platelet aggregation and activation using impedance aggregometry and flow cytometry.
Time frame: From enrollment to 12 months of follow-up. Measured at 3 time points.
Platelet levels of HSP47 in association to fibrinolytic capacity
The level of HSP47 on platelets will be measured in a bloodsample. It will be measured using proteomics and flow cytometry. Fibrinolytic capacity will be assessed by ROTEM (R) tPA methods established in our lab, and by plasma fibrinolysis analyses.
Time frame: From enrollment to 12 months of follow-up. Measured at 3 time points.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.